Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,419
archived clinical trials in
Pulmonary

Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis
Multicenter, Randomized, Open Label Trial to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis
Status: Enrolling
Updated:  2/5/2016
Emory University Hospital
mi
from
Atlanta, GA
Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis
Multicenter, Randomized, Open Label Trial to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis
Status: Enrolling
Updated: 2/5/2016
Emory University Hospital
mi
from
Atlanta, GA
Click here to add this to my saved trials
Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis
Multicenter, Randomized, Open Label Trial to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis
Status: Enrolling
Updated:  2/5/2016
Johns Hopkins University
mi
from
Baltiomore, MD
Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis
Multicenter, Randomized, Open Label Trial to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis
Status: Enrolling
Updated: 2/5/2016
Johns Hopkins University
mi
from
Baltiomore, MD
Click here to add this to my saved trials
Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis
Multicenter, Randomized, Open Label Trial to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis
Status: Enrolling
Updated:  2/5/2016
Oregon Health and Science University
mi
from
Portland, OR
Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis
Multicenter, Randomized, Open Label Trial to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis
Status: Enrolling
Updated: 2/5/2016
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis
Multicenter, Randomized, Open Label Trial to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis
Status: Enrolling
Updated:  2/5/2016
CLC Pulmonary Hypertension Clinic Division of Pulmonary, Allergy and Critical Care Medicine UPMC
mi
from
Pittsburgh, PA
Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis
Multicenter, Randomized, Open Label Trial to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis
Status: Enrolling
Updated: 2/5/2016
CLC Pulmonary Hypertension Clinic Division of Pulmonary, Allergy and Critical Care Medicine UPMC
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Caregiver Outlook: An Intervention to Improve Caregiving in Serious Illness
Caregiver Outlook: An Intervention to Improve Caregiving in Serious Illness
Status: Enrolling
Updated:  2/8/2016
Durham VA Medical Center, Durham, NC
mi
from
Durham, NC
Caregiver Outlook: An Intervention to Improve Caregiving in Serious Illness
Caregiver Outlook: An Intervention to Improve Caregiving in Serious Illness
Status: Enrolling
Updated: 2/8/2016
Durham VA Medical Center, Durham, NC
mi
from
Durham, NC
Click here to add this to my saved trials
Hypertonic Saline With Dextran for Treating Hypovolemic Shock and Severe Brain Injury
Effect of Hypertonic Resuscitation for Blunt Trauma
Status: Enrolling
Updated:  2/8/2016
Univ of Washington
mi
from
Seattle, WA
Hypertonic Saline With Dextran for Treating Hypovolemic Shock and Severe Brain Injury
Effect of Hypertonic Resuscitation for Blunt Trauma
Status: Enrolling
Updated: 2/8/2016
Univ of Washington
mi
from
Seattle, WA
Click here to add this to my saved trials
The Effects of Sound Energy on Pulmonary Gas Exchange
The Effects of Sound Energy on Pulmonary Gas Exchange
Status: Enrolling
Updated:  2/9/2016
Loma Linda University Medical Center
mi
from
Loma Linda, CA
The Effects of Sound Energy on Pulmonary Gas Exchange
The Effects of Sound Energy on Pulmonary Gas Exchange
Status: Enrolling
Updated: 2/9/2016
Loma Linda University Medical Center
mi
from
Loma Linda, CA
Click here to add this to my saved trials
BAY 43-9006 in Previously Untreated Patients With Non-Small Cell Lung Cancer (NSCLC)
Phase I Dose-Escalating, Open-Label, Non-Placebo Controlled Study of BAY 43-9006 (Sorafenib) in Combination With Carboplatin, Paclitaxel and Bevacizumab in Previously Untreated Patients With Stage IIIB (With Malignant Pleural Effusions) or Stage IV Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  2/9/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
BAY 43-9006 in Previously Untreated Patients With Non-Small Cell Lung Cancer (NSCLC)
Phase I Dose-Escalating, Open-Label, Non-Placebo Controlled Study of BAY 43-9006 (Sorafenib) in Combination With Carboplatin, Paclitaxel and Bevacizumab in Previously Untreated Patients With Stage IIIB (With Malignant Pleural Effusions) or Stage IV Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 2/9/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Early Methicillin-resistant Staphylococcus Aureus (MRSA) Therapy in Cystic Fibrosis (CF)
Early MRSA Therapy in CF - Culture Based vs. Observant Therapy (Treat or Observe) (Star-TOO - STaph Aureus Resistance - Treat or Observe)
Status: Enrolling
Updated:  2/10/2016
Baylor College of Medicine
mi
from
Houston, TX
Early Methicillin-resistant Staphylococcus Aureus (MRSA) Therapy in Cystic Fibrosis (CF)
Early MRSA Therapy in CF - Culture Based vs. Observant Therapy (Treat or Observe) (Star-TOO - STaph Aureus Resistance - Treat or Observe)
Status: Enrolling
Updated: 2/10/2016
Baylor College of Medicine
mi
from
Houston, TX
Click here to add this to my saved trials
Early Methicillin-resistant Staphylococcus Aureus (MRSA) Therapy in Cystic Fibrosis (CF)
Early MRSA Therapy in CF - Culture Based vs. Observant Therapy (Treat or Observe) (Star-TOO - STaph Aureus Resistance - Treat or Observe)
Status: Enrolling
Updated:  2/10/2016
CFF Care Center & Pediatric Program Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Early Methicillin-resistant Staphylococcus Aureus (MRSA) Therapy in Cystic Fibrosis (CF)
Early MRSA Therapy in CF - Culture Based vs. Observant Therapy (Treat or Observe) (Star-TOO - STaph Aureus Resistance - Treat or Observe)
Status: Enrolling
Updated: 2/10/2016
CFF Care Center & Pediatric Program Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Early Methicillin-resistant Staphylococcus Aureus (MRSA) Therapy in Cystic Fibrosis (CF)
Early MRSA Therapy in CF - Culture Based vs. Observant Therapy (Treat or Observe) (Star-TOO - STaph Aureus Resistance - Treat or Observe)
Status: Enrolling
Updated:  2/10/2016
Children's Hospitals and Clinics of Minnesota - Minneapolis
mi
from
Minneapolis, MN
Early Methicillin-resistant Staphylococcus Aureus (MRSA) Therapy in Cystic Fibrosis (CF)
Early MRSA Therapy in CF - Culture Based vs. Observant Therapy (Treat or Observe) (Star-TOO - STaph Aureus Resistance - Treat or Observe)
Status: Enrolling
Updated: 2/10/2016
Children's Hospitals and Clinics of Minnesota - Minneapolis
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Early Methicillin-resistant Staphylococcus Aureus (MRSA) Therapy in Cystic Fibrosis (CF)
Early MRSA Therapy in CF - Culture Based vs. Observant Therapy (Treat or Observe) (Star-TOO - STaph Aureus Resistance - Treat or Observe)
Status: Enrolling
Updated:  2/10/2016
Cook Children's Medical Center
mi
from
Fort Worth, TX
Early Methicillin-resistant Staphylococcus Aureus (MRSA) Therapy in Cystic Fibrosis (CF)
Early MRSA Therapy in CF - Culture Based vs. Observant Therapy (Treat or Observe) (Star-TOO - STaph Aureus Resistance - Treat or Observe)
Status: Enrolling
Updated: 2/10/2016
Cook Children's Medical Center
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Early Methicillin-resistant Staphylococcus Aureus (MRSA) Therapy in Cystic Fibrosis (CF)
Early MRSA Therapy in CF - Culture Based vs. Observant Therapy (Treat or Observe) (Star-TOO - STaph Aureus Resistance - Treat or Observe)
Status: Enrolling
Updated:  2/10/2016
N.C Memorial Hospital and N.C Children's Hospital
mi
from
Chapel Hill, NC
Early Methicillin-resistant Staphylococcus Aureus (MRSA) Therapy in Cystic Fibrosis (CF)
Early MRSA Therapy in CF - Culture Based vs. Observant Therapy (Treat or Observe) (Star-TOO - STaph Aureus Resistance - Treat or Observe)
Status: Enrolling
Updated: 2/10/2016
N.C Memorial Hospital and N.C Children's Hospital
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Early Methicillin-resistant Staphylococcus Aureus (MRSA) Therapy in Cystic Fibrosis (CF)
Early MRSA Therapy in CF - Culture Based vs. Observant Therapy (Treat or Observe) (Star-TOO - STaph Aureus Resistance - Treat or Observe)
Status: Enrolling
Updated:  2/10/2016
Seattle Children's
mi
from
Seattle, WA
Early Methicillin-resistant Staphylococcus Aureus (MRSA) Therapy in Cystic Fibrosis (CF)
Early MRSA Therapy in CF - Culture Based vs. Observant Therapy (Treat or Observe) (Star-TOO - STaph Aureus Resistance - Treat or Observe)
Status: Enrolling
Updated: 2/10/2016
Seattle Children's
mi
from
Seattle, WA
Click here to add this to my saved trials
Early Methicillin-resistant Staphylococcus Aureus (MRSA) Therapy in Cystic Fibrosis (CF)
Early MRSA Therapy in CF - Culture Based vs. Observant Therapy (Treat or Observe) (Star-TOO - STaph Aureus Resistance - Treat or Observe)
Status: Enrolling
Updated:  2/10/2016
St. Louis Children's Hospital
mi
from
St. Louis, MO
Early Methicillin-resistant Staphylococcus Aureus (MRSA) Therapy in Cystic Fibrosis (CF)
Early MRSA Therapy in CF - Culture Based vs. Observant Therapy (Treat or Observe) (Star-TOO - STaph Aureus Resistance - Treat or Observe)
Status: Enrolling
Updated: 2/10/2016
St. Louis Children's Hospital
mi
from
St. Louis, MO
Click here to add this to my saved trials
Early Methicillin-resistant Staphylococcus Aureus (MRSA) Therapy in Cystic Fibrosis (CF)
Early MRSA Therapy in CF - Culture Based vs. Observant Therapy (Treat or Observe) (Star-TOO - STaph Aureus Resistance - Treat or Observe)
Status: Enrolling
Updated:  2/10/2016
Children'S Hospital
mi
from
Aurora, CO
Early Methicillin-resistant Staphylococcus Aureus (MRSA) Therapy in Cystic Fibrosis (CF)
Early MRSA Therapy in CF - Culture Based vs. Observant Therapy (Treat or Observe) (Star-TOO - STaph Aureus Resistance - Treat or Observe)
Status: Enrolling
Updated: 2/10/2016
Children'S Hospital
mi
from
Aurora, CO
Click here to add this to my saved trials
Early Methicillin-resistant Staphylococcus Aureus (MRSA) Therapy in Cystic Fibrosis (CF)
Early MRSA Therapy in CF - Culture Based vs. Observant Therapy (Treat or Observe) (Star-TOO - STaph Aureus Resistance - Treat or Observe)
Status: Enrolling
Updated:  2/10/2016
The Children's Hospital-University of Birmingham
mi
from
Birmingham, AL
Early Methicillin-resistant Staphylococcus Aureus (MRSA) Therapy in Cystic Fibrosis (CF)
Early MRSA Therapy in CF - Culture Based vs. Observant Therapy (Treat or Observe) (Star-TOO - STaph Aureus Resistance - Treat or Observe)
Status: Enrolling
Updated: 2/10/2016
The Children's Hospital-University of Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Early Methicillin-resistant Staphylococcus Aureus (MRSA) Therapy in Cystic Fibrosis (CF)
Early MRSA Therapy in CF - Culture Based vs. Observant Therapy (Treat or Observe) (Star-TOO - STaph Aureus Resistance - Treat or Observe)
Status: Enrolling
Updated:  2/10/2016
University of Florida
mi
from
Gainesville, FL
Early Methicillin-resistant Staphylococcus Aureus (MRSA) Therapy in Cystic Fibrosis (CF)
Early MRSA Therapy in CF - Culture Based vs. Observant Therapy (Treat or Observe) (Star-TOO - STaph Aureus Resistance - Treat or Observe)
Status: Enrolling
Updated: 2/10/2016
University of Florida
mi
from
Gainesville, FL
Click here to add this to my saved trials
Early Methicillin-resistant Staphylococcus Aureus (MRSA) Therapy in Cystic Fibrosis (CF)
Early MRSA Therapy in CF - Culture Based vs. Observant Therapy (Treat or Observe) (Star-TOO - STaph Aureus Resistance - Treat or Observe)
Status: Enrolling
Updated:  2/10/2016
University of Michigan Health System
mi
from
Ann Arbor, MI
Early Methicillin-resistant Staphylococcus Aureus (MRSA) Therapy in Cystic Fibrosis (CF)
Early MRSA Therapy in CF - Culture Based vs. Observant Therapy (Treat or Observe) (Star-TOO - STaph Aureus Resistance - Treat or Observe)
Status: Enrolling
Updated: 2/10/2016
University of Michigan Health System
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Early Methicillin-resistant Staphylococcus Aureus (MRSA) Therapy in Cystic Fibrosis (CF)
Early MRSA Therapy in CF - Culture Based vs. Observant Therapy (Treat or Observe) (Star-TOO - STaph Aureus Resistance - Treat or Observe)
Status: Enrolling
Updated:  2/10/2016
University of Texas Southwestern Medical Center
mi
from
Dallas, TX
Early Methicillin-resistant Staphylococcus Aureus (MRSA) Therapy in Cystic Fibrosis (CF)
Early MRSA Therapy in CF - Culture Based vs. Observant Therapy (Treat or Observe) (Star-TOO - STaph Aureus Resistance - Treat or Observe)
Status: Enrolling
Updated: 2/10/2016
University of Texas Southwestern Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Early Methicillin-resistant Staphylococcus Aureus (MRSA) Therapy in Cystic Fibrosis (CF)
Early MRSA Therapy in CF - Culture Based vs. Observant Therapy (Treat or Observe) (Star-TOO - STaph Aureus Resistance - Treat or Observe)
Status: Enrolling
Updated:  2/10/2016
University of Washington Medical Center
mi
from
Seattle, WA
Early Methicillin-resistant Staphylococcus Aureus (MRSA) Therapy in Cystic Fibrosis (CF)
Early MRSA Therapy in CF - Culture Based vs. Observant Therapy (Treat or Observe) (Star-TOO - STaph Aureus Resistance - Treat or Observe)
Status: Enrolling
Updated: 2/10/2016
University of Washington Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Safety Study of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
An Open-Label, Phase 2 Study of the Safety of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated:  2/10/2016
Clinical Research Facility
mi
from
Phoenix, AZ
Safety Study of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
An Open-Label, Phase 2 Study of the Safety of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated: 2/10/2016
Clinical Research Facility
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Safety Study of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
An Open-Label, Phase 2 Study of the Safety of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated:  2/10/2016
Clinical Research Facility
mi
from
Pomona, CA
Safety Study of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
An Open-Label, Phase 2 Study of the Safety of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated: 2/10/2016
Clinical Research Facility
mi
from
Pomona, CA
Click here to add this to my saved trials
Safety Study of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
An Open-Label, Phase 2 Study of the Safety of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated:  2/10/2016
Clinical Research Facility
mi
from
San Jose, CA
Safety Study of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
An Open-Label, Phase 2 Study of the Safety of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated: 2/10/2016
Clinical Research Facility
mi
from
San Jose, CA
Click here to add this to my saved trials
Safety Study of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
An Open-Label, Phase 2 Study of the Safety of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated:  2/10/2016
Clinical Research Facility
mi
from
New Haven, CT
Safety Study of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
An Open-Label, Phase 2 Study of the Safety of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated: 2/10/2016
Clinical Research Facility
mi
from
New Haven, CT
Click here to add this to my saved trials
Safety Study of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
An Open-Label, Phase 2 Study of the Safety of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated:  2/10/2016
Clinical Research Facility
mi
from
Sarasota, FL
Safety Study of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
An Open-Label, Phase 2 Study of the Safety of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated: 2/10/2016
Clinical Research Facility
mi
from
Sarasota, FL
Click here to add this to my saved trials
Safety Study of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
An Open-Label, Phase 2 Study of the Safety of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated:  2/10/2016
Clinical Research Facility
mi
from
Atlanta, GA
Safety Study of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
An Open-Label, Phase 2 Study of the Safety of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated: 2/10/2016
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
Safety Study of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
An Open-Label, Phase 2 Study of the Safety of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated:  2/10/2016
Clinical Research Facility
mi
from
Kailua, HI
Safety Study of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
An Open-Label, Phase 2 Study of the Safety of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated: 2/10/2016
Clinical Research Facility
mi
from
Kailua, HI
Click here to add this to my saved trials
Safety Study of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
An Open-Label, Phase 2 Study of the Safety of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated:  2/10/2016
mi
from
Lahaina, HI
Safety Study of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
An Open-Label, Phase 2 Study of the Safety of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated: 2/10/2016
mi
from
Lahaina, HI
Click here to add this to my saved trials
Safety Study of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
An Open-Label, Phase 2 Study of the Safety of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated:  2/10/2016
Clinical Research Facility
mi
from
Nampa, ID
Safety Study of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
An Open-Label, Phase 2 Study of the Safety of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated: 2/10/2016
Clinical Research Facility
mi
from
Nampa, ID
Click here to add this to my saved trials
Safety Study of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
An Open-Label, Phase 2 Study of the Safety of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated:  2/10/2016
Clinical Research Facility
mi
from
Elk Grove Village, IL
Safety Study of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
An Open-Label, Phase 2 Study of the Safety of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated: 2/10/2016
Clinical Research Facility
mi
from
Elk Grove Village, IL
Click here to add this to my saved trials
Safety Study of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
An Open-Label, Phase 2 Study of the Safety of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated:  2/10/2016
Clinical Research Facility
mi
from
Boston, MA
Safety Study of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
An Open-Label, Phase 2 Study of the Safety of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated: 2/10/2016
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
Safety Study of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
An Open-Label, Phase 2 Study of the Safety of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated:  2/10/2016
Clinical Research Facility
mi
from
West Roxbury, MA
Safety Study of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
An Open-Label, Phase 2 Study of the Safety of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated: 2/10/2016
Clinical Research Facility
mi
from
West Roxbury, MA
Click here to add this to my saved trials
Safety Study of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
An Open-Label, Phase 2 Study of the Safety of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated:  2/10/2016
Clinical Research Facility
mi
from
St. Louis, MO
Safety Study of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
An Open-Label, Phase 2 Study of the Safety of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated: 2/10/2016
Clinical Research Facility
mi
from
St. Louis, MO
Click here to add this to my saved trials
Safety Study of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
An Open-Label, Phase 2 Study of the Safety of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated:  2/10/2016
mi
from
Huntington Station, NY
Safety Study of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
An Open-Label, Phase 2 Study of the Safety of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated: 2/10/2016
mi
from
Huntington Station, NY
Click here to add this to my saved trials
Safety Study of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
An Open-Label, Phase 2 Study of the Safety of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated:  2/10/2016
Clinical Research Facility
mi
from
New York, NY
Safety Study of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
An Open-Label, Phase 2 Study of the Safety of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated: 2/10/2016
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
Safety Study of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
An Open-Label, Phase 2 Study of the Safety of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated:  2/10/2016
Clinical Research Facility
mi
from
Rochester, NY
Safety Study of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
An Open-Label, Phase 2 Study of the Safety of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated: 2/10/2016
Clinical Research Facility
mi
from
Rochester, NY
Click here to add this to my saved trials
Safety Study of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
An Open-Label, Phase 2 Study of the Safety of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated:  2/10/2016
Clinical Research Facility
mi
from
Worthington, OH
Safety Study of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
An Open-Label, Phase 2 Study of the Safety of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated: 2/10/2016
Clinical Research Facility
mi
from
Worthington, OH
Click here to add this to my saved trials
Safety Study of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
An Open-Label, Phase 2 Study of the Safety of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated:  2/10/2016
Clinical Research Facility
mi
from
Portland, OR
Safety Study of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
An Open-Label, Phase 2 Study of the Safety of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated: 2/10/2016
Clinical Research Facility
mi
from
Portland, OR
Click here to add this to my saved trials
Safety Study of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
An Open-Label, Phase 2 Study of the Safety of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated:  2/10/2016
Clinical Research Facility
mi
from
Lancaster, PA
Safety Study of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
An Open-Label, Phase 2 Study of the Safety of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated: 2/10/2016
Clinical Research Facility
mi
from
Lancaster, PA
Click here to add this to my saved trials
Safety Study of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
An Open-Label, Phase 2 Study of the Safety of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated:  2/10/2016
Clinical Research Facility
mi
from
Dallas, TX
Safety Study of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
An Open-Label, Phase 2 Study of the Safety of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated: 2/10/2016
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Safety Study of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
An Open-Label, Phase 2 Study of the Safety of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated:  2/10/2016
Clinical Research Facility
mi
from
Houston, TX
Safety Study of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
An Open-Label, Phase 2 Study of the Safety of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated: 2/10/2016
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Safety Study of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
An Open-Label, Phase 2 Study of the Safety of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated:  2/10/2016
Clinical Research Facility
mi
from
San Antonio, TX
Safety Study of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
An Open-Label, Phase 2 Study of the Safety of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated: 2/10/2016
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
Safety Study of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
An Open-Label, Phase 2 Study of the Safety of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated:  2/10/2016
Clinical Research Facility
mi
from
Provo, UT
Safety Study of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
An Open-Label, Phase 2 Study of the Safety of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated: 2/10/2016
Clinical Research Facility
mi
from
Provo, UT
Click here to add this to my saved trials
Safety Study of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
An Open-Label, Phase 2 Study of the Safety of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated:  2/10/2016
Clinical Research Facility
mi
from
Annandale, VA
Safety Study of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
An Open-Label, Phase 2 Study of the Safety of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated: 2/10/2016
Clinical Research Facility
mi
from
Annandale, VA
Click here to add this to my saved trials
Safety Study of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
An Open-Label, Phase 2 Study of the Safety of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated:  2/10/2016
Clinical Research Facility
mi
from
Bremerton, WA
Safety Study of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
An Open-Label, Phase 2 Study of the Safety of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated: 2/10/2016
Clinical Research Facility
mi
from
Bremerton, WA
Click here to add this to my saved trials
Malignant Pleural Effusion With ZD6474
Treatment of Malignant Pleural Effusion With ZD6474, a Novel Vascular Endothelial Growth Factor Receptor (VEGFR) and Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor
Status: Enrolling
Updated:  2/11/2016
UT MD Anderson Cancer Center
mi
from
Houston, TX
Malignant Pleural Effusion With ZD6474
Treatment of Malignant Pleural Effusion With ZD6474, a Novel Vascular Endothelial Growth Factor Receptor (VEGFR) and Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor
Status: Enrolling
Updated: 2/11/2016
UT MD Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Mechanisms of Immune Tolerance and Inflammation in Patients With Cystic Fibrosis With ABPA
SCCOR in Host Factors in Chronic Lung Diseases: Mechanisms of Immune Tolerance and Inflammation in Allergic Bronchopulmonary Aspergillosis (ABPA) in Patients With Cystic Fibrosis
Status: Enrolling
Updated:  2/12/2016
Children's Hospital of Pittsburgh of UPMC
mi
from
Pittsburgh, PA
Mechanisms of Immune Tolerance and Inflammation in Patients With Cystic Fibrosis With ABPA
SCCOR in Host Factors in Chronic Lung Diseases: Mechanisms of Immune Tolerance and Inflammation in Allergic Bronchopulmonary Aspergillosis (ABPA) in Patients With Cystic Fibrosis
Status: Enrolling
Updated: 2/12/2016
Children's Hospital of Pittsburgh of UPMC
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Evaluate Safety of Technosphere® Insulin (TI) in Diabetic Subjects With Moderate Obstructive Pulmonary Disease
A Phase 3, Open-label, Randomized Clinical Trial to Evaluate the Safety of Technosphere® Insulin Inhalation Powder in Type 1 or Type 2 Diabetic Subjects With Obstructive Pulmonary Disease (Asthma or Chronic Obstructive Pulmonary Disease) Over a 12 Months Treatment Period With a 2 Month Follow-up
Status: Enrolling
Updated:  2/12/2016
Clinical Research Facility
mi
from
Mission Hills, CA
Evaluate Safety of Technosphere® Insulin (TI) in Diabetic Subjects With Moderate Obstructive Pulmonary Disease
A Phase 3, Open-label, Randomized Clinical Trial to Evaluate the Safety of Technosphere® Insulin Inhalation Powder in Type 1 or Type 2 Diabetic Subjects With Obstructive Pulmonary Disease (Asthma or Chronic Obstructive Pulmonary Disease) Over a 12 Months Treatment Period With a 2 Month Follow-up
Status: Enrolling
Updated: 2/12/2016
Clinical Research Facility
mi
from
Mission Hills, CA
Click here to add this to my saved trials
Evaluate Safety of Technosphere® Insulin (TI) in Diabetic Subjects With Moderate Obstructive Pulmonary Disease
A Phase 3, Open-label, Randomized Clinical Trial to Evaluate the Safety of Technosphere® Insulin Inhalation Powder in Type 1 or Type 2 Diabetic Subjects With Obstructive Pulmonary Disease (Asthma or Chronic Obstructive Pulmonary Disease) Over a 12 Months Treatment Period With a 2 Month Follow-up
Status: Enrolling
Updated:  2/12/2016
Clinical Research Facility
mi
from
San Diego, CA
Evaluate Safety of Technosphere® Insulin (TI) in Diabetic Subjects With Moderate Obstructive Pulmonary Disease
A Phase 3, Open-label, Randomized Clinical Trial to Evaluate the Safety of Technosphere® Insulin Inhalation Powder in Type 1 or Type 2 Diabetic Subjects With Obstructive Pulmonary Disease (Asthma or Chronic Obstructive Pulmonary Disease) Over a 12 Months Treatment Period With a 2 Month Follow-up
Status: Enrolling
Updated: 2/12/2016
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials